Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer
Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx
Sponsor: Biotech Pharmaceutical Co., Ltd.
A PHASE2 clinical study on Hypopharyngeal Cancer and Oropharyngeal Cancer, this trial is ongoing. The trial is conducted by Biotech Pharmaceutical Co., Ltd. and has accumulated 7 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — Apr 2018 [monthly]
Recruiting PHASE2
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biotech Pharmaceutical Co., Ltd.
- The Second People's Hospital of Sichuan
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baotou, China , Chengdu, China , Chongqing, China , Guiyang, China , Kunming, China , Lanzhou, China , Nanning, China , Xian, China , Xining, China , Xi’an, China and 2 more locations